A phase I/II multicentre trial (ECHO-202/KEYNOTE-037) performed also in HNSCC subjects, is evaluating treatment with epacadostat, a highly selective IDO-1 enzyme inhibitor plus pembrolizumab (anti-PD-1) in patients with advanced solid tumours. Here, PDCD1 is linked to head and neck squamous cell carcinoma.